Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.1%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded up 8.1% during mid-day trading on Friday . The stock traded as high as $26.67 and last traded at $25.96. 25,007 shares changed hands during trading, a decline of 83% from the average session volume of 143,955 shares. The stock had previously closed at $24.01.

Analysts Set New Price Targets

A number of analysts have commented on DNTH shares. Jefferies Financial Group upped their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Raymond James boosted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, April 18th. Wedbush raised their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd. Finally, Stifel Nicolaus began coverage on Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $42.40.

Dianthus Therapeutics Stock Up 7.5 %

The company’s 50 day simple moving average is $25.53 and its 200-day simple moving average is $17.86.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.73 million. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $28,961,000. Acadian Asset Management LLC acquired a new stake in Dianthus Therapeutics during the third quarter worth approximately $303,000. Atlas Venture Life Science Advisors LLC acquired a new stake in Dianthus Therapeutics in the 3rd quarter worth about $3,240,000. Avidity Partners Management LP purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter worth about $16,644,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at about $497,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.